Donna Weber

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

33h-index6.1kcitations132works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(112), Protein Degradation and Inhibitors(42), Cancer Treatment and Pharmacology(38), Amyloidosis: Diagnosis, Treatment, Outcomes(11), Chronic Lymphocytic Leukemia Research(10)

Publications131 total

Prognostic impact of CXCR4 mutation type on clinical features and outcomes of patients with Waldenström macroglobulinemia
Blood·2025Open Access
Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM)
Blood·2025Open Access
Single-cell transcriptomic and clonotypic characterization of Waldenström macroglobulinemia reveals intra-patient monoclonal diversity with distinct differentiation states
Blood·2025Open Access
Final results of a multi-center phase 2 trial of isatuximab-lenalidomide in patients with high risk smoldering multiple myeloma (HRSMM)
Blood·2025Open Access
BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma
Blood·2025Open Access
Treatment history, not race or duffy-null status, predicts outcomes with teclistamab in Relapsed/Refractory multiple myeloma
Blood·2025Open Access
Genomic Profiling of Multiple Myeloma via Optical Genome Mapping: An Exploratory Analysis of Response and Progression in Newly Diagnosed and Relapsed Disease
Clinical Lymphoma Myeloma & Leukemia·2025
NSO-04 Evaluation of Clinical Outcomes and Toxicities in Multiple Myeloma Patients Receiving Commercial Talquetamab
Clinical Lymphoma Myeloma & Leukemia·2024
P-321 Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation
Clinical Lymphoma Myeloma & Leukemia·2024
P-017 Impact of Genetic Ancestry on Outcomes and Toxicity of Ide-cel in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Clinical Lymphoma Myeloma & Leukemia·2024
OA-43 Interim Results of a Phase 2 Trial of Isatuximab-Lenalidomide for Patients with High-Risk Smoldering Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2024
OA-36 SBCMA predicts progression and is a biomarker of response in myeloma precursor disease followed on prospective studies
Clinical Lymphoma Myeloma & Leukemia·2023· 1 cited
NSO-02 Characteristics of multiple myeloma patients with central nervous system involvement
Clinical Lymphoma Myeloma & Leukemia·2023
MM-403 Impact of Clonal Plasma Cells in Autografts on the Outcome of High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant
Clinical Lymphoma Myeloma & Leukemia·2022· 1 cited
CT-511 Clinical Characteristics and Response Outcomes in Older Multiple Myeloma Patients Who Received Idecabtagene Vicleucel: A Single Center Study
Clinical Lymphoma Myeloma & Leukemia·2022· 1 cited
Poster: MM-403 Impact of Clonal Plasma Cells in Autografts on the Outcome of High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant
Clinical Lymphoma Myeloma & Leukemia·2022
Poster: CT-511 Clinical Characteristics and Response Outcomes in Older Multiple Myeloma Patients Who Received Idecabtagene Vicleucel: A Single Center Study
Clinical Lymphoma Myeloma & Leukemia·2022
P-233: Retrospective, single-center, real-world experience of belantamab mafodotin in relapsed/refractory multiple myeloma
Clinical Lymphoma Myeloma & Leukemia·2022
Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hemaptopoietic Stem Cell Transplantation
Transplantation and Cellular Therapy·2022
KRD vs. VRD as Induction before Autologous Hematopoietic Progenitor Cell Transplantation for High-Risk Newly Diagnosed Multiple Myeloma
Transplantation and Cellular Therapy·2022
page 1 of 7Next →

Frequent Co-authors

Raymond Alexanian(19), Meletios Α. Dimopoulos(15), Kay Delasalle(11), Robert Knight(9), Carol Ann Huff(8), Keith Stockerl‐Goldstein(8), Sheeba K. Thomas(8), Richard E. Champlin(8), Rashmi Kumar(7), Michael Wang(7), Shaji Kumar(6), Caitlin Costello(6), Kelly Godby(6), Michaela Liedtke(6), Noopur Raje(6), Seema Singhal(6), Muzaffar H. Qazilbash(6), Sergio Giralt(6), Robert Z. Orlowski(6), Zhinuan Yu(6)